Results 91 to 100 of about 2,519,772 (150)

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease. [PDF]

Biol Direct, 2023
Lee SM, Jun DW, Yoon EL, Oh JH, Roh YJ, Lee EJ, Shin JH, Nam YD, Kim HS.   +8 more
europepmc   +1 more source

Obeticholic acid alleviates lupus pathology by inhibiting T follicular helper cell differentiation. [PDF]

EMBO Mol Med
Kang M, Park J, Lee J, Won Kim S, Lee Y.
europepmc   +1 more source

Impact of Obeticholic Acid Therapy on Insulin Resistance and Metabolic Parameters in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). [PDF]

Int J Hepatol
Almansouri M, Shalabi H, Karami M, Alharthy O, Kabli A, Khalil M, Alkhattabi M, Mirdad D, Alharthy A, Abduljabbar A, Wazzan M, Alabsi H, Maidin SS, Waseem H, Hassan A.   +14 more
europepmc   +1 more source

A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH.

, 2019
A significantly higher proportion of patients with nonalcoholic steatohepatitis (NASH) who received obeticholic acid (OCA) had histological improvement relative to placebo in the FLINT (farnesoid X nuclear receptor ligand obeticholic acid for ...
Bhatnagar, Pallav, Guo, Xiuqing, Chalasani, Naga, Loomba, Rohit, Wilson, Laura A, Pillai, Sreekumar, Chen, Yii-Der Ida, Lauzon, Marie, Rotter, Jerome I, Kowdley, Kris V, Taylor, Kent D, Cummings, Oscar W, Gawrieh, Samer, Yates, Katherine, Tan, Jingyi   +14 more
core  

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status. [PDF]

Euroasian J Hepatogastroenterol, 2022
Roy PP, Mahtab MA, Rahim MA, Yesmin SS, Islam SB, Akbar SMF.   +5 more
europepmc   +1 more source

Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals. [PDF]

Hepatol Commun, 2023
Ng CH, Tang ASP, Xiao J, Wong ZY, Yong JN, Fu CE, Zeng RW, Tan C, Wong GHZ, Teng M, Chee D, Tan DJH, Chan KE, Huang DQ, Chew NWS, Nah B, Siddqui MS, Sanyal AJ, Noureddin M, Muthiah M.   +19 more
europepmc   +1 more source

Obeticholic acid as an index farnesoid X receptor scaffold in metabolic dysfunction-associated steatohepatitis: a testable model for efficacy-liability separation and biomarker interpretation. [PDF]

Front Pharmacol
Liu J, Wu X.
europepmc   +1 more source

Activation of Brown Adipocytes by Farnesoid X Receptor Agonist, Obeticholic Acid-A Potential Novel Therapeutic Avenue in the Management of Obesity. [PDF]

J Clin Med
Dąbrowska AM, Chwil M, Urbańska EM.
europepmc   +1 more source

A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection. [PDF]

Inflammopharmacology, 2023
Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Youssef FS, El-Sherbeni SA, Negm WA.   +5 more
europepmc   +1 more source

Transcriptional and Post-Transcriptional Anticholestatic Mechanisms of Obeticholic Acid in Lipopolysaccharide-Induced Cholestasis. [PDF]

Pharmaceutics
Razori MV, Hillotte GL, Martín PL, Barosso IR, Basiglio CL, Ruiz ML, Roma MG.   +6 more
europepmc   +1 more source